<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02034955</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 12-5318-C</org_study_id>
    <nct_id>NCT02034955</nct_id>
  </id_info>
  <brief_title>Prostatectomy Adaptive Radiation Therapy (ART)</brief_title>
  <official_title>A Feasibility Study of Post-operative Adaptive Radiation Therapy for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will ultimately aim to evaluate the side effects of treatment by asking 20&#xD;
      subjects to receive post-operative radiotherapy for prostate cancer with the treatment plan&#xD;
      adapted after the first week of treatment to account for changes in the target shape. These&#xD;
      patients will be asked to complete toxicity scores and a quality of life questionnaire at the&#xD;
      start and completion of treatment, and at 3 months 1, 2 and 5 years from the start of&#xD;
      radiotherapy. These results will be used to determine the feasibility of the proposed&#xD;
      approach, and obtain early estimates of improvements in uncertainty margin requirements for&#xD;
      this population of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in radiation dose delivered to target volumes and normal tissue</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time for radiotherapy replanning</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric modulated arc therapy impact in a clinical adaptive Radiotherapy workflow.</measure>
    <time_frame>5 years</time_frame>
    <description>Feasibility will be assessed by the time required to perform the adaptive intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity associated with the adaptive radiotherapy technique.</measure>
    <time_frame>5 years</time_frame>
    <description>Assessments of gastrointestinal and genitourinary complications using the Common Toxicity Criteria for Adverse Events scoring system and the Expanded Prostate Cancer Index Composite questionnaire.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Post-Operative adaptive radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Post-operative Adaptive Radiation Therapy</intervention_name>
    <arm_group_label>Post-Operative adaptive radiotherapy</arm_group_label>
    <other_name>All Patients enrolled in this study will have additional scans (Cone-Beam CT,MRI) daily during their treatment. This extra imaging will help us see any</other_name>
    <other_name>changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of adenocarcinoma of the prostate after radical prostatectomy AND&#xD;
&#xD;
          -  Clinical stage pT3, pT4, or pT2 with positive margin OR&#xD;
&#xD;
          -  Any p-Stage with a persistently elevated post-operative PSA &gt; 0.05 ng/ml OR&#xD;
&#xD;
          -  A delayed rise in PSA post-operatively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inflammatory bowel disease or other contraindications to radiotherapy&#xD;
&#xD;
          -  Prior pelvic radiotherapy&#xD;
&#xD;
          -  Previous cytotoxic chemotherapy&#xD;
&#xD;
          -  Radiological or pathologic evidence of nodal metastases.&#xD;
&#xD;
          -  Planned radiotherapy to pelvic lymph nodes&#xD;
&#xD;
          -  Evidence of systemic metastases on imaging.&#xD;
&#xD;
          -  Prosthetic hip replacement&#xD;
&#xD;
          -  No signed informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles N Catton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network--Princess Margaret Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Adaptive Radiotherapy</keyword>
  <keyword>Prostatectomy</keyword>
  <keyword>Patients who had a prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

